Expert Review of Cardiovascular Therapy最新文献

The staging of cardiac damage for mitral regurgitation: ready for prime time? 二尖瓣返流的心脏损伤分期：准备好了吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-13 DOI: 10.1080/14779072.2025.2561070

Michail Penteris, Anastasia Kalogirou, Konstantinos Lampropoulos

{"title":"The staging of cardiac damage for mitral regurgitation: ready for prime time?","authors":"Michail Penteris, Anastasia Kalogirou, Konstantinos Lampropoulos","doi":"10.1080/14779072.2025.2561070","DOIUrl":"10.1080/14779072.2025.2561070","url":null,"abstract":"Introduction: Mitral regurgitation (MR) is a progressive valvular heart disease (VHD) with significant morbidity and mortality, particularly in older adults. Current guidelines rely primarily on symptom status and LV function to guide intervention, which may underestimate disease severity, especially in asymptomatic patients.Areas covered: A comprehensive literature search was conducted in PubMed/Medline, Scopus and EMBASE databases for articles until March 2025. This review discusses MR severity grading and introduces the concept of extra-mitral cardiac damage staging, adapted from models used in aortic stenosis. It highlights the application of this staging to both primary and secondary MR, detailing how structural and functional deterioration beyond the mitral valve, such as involvement of the LV, left atrium, pulmonary vasculature, and right ventricle, correlates with outcomes.Expert opinion: Cardiac damage staging offers a practical, echocardiography-based tool for personalized risk assessment. It allows for the earlier identification of high-risk patients and may shift intervention timing, especially for transcatheter therapies. Despite some variability in staging definitions, its integration into clinical practice could enhance patient stratification and management. Future research should aim to standardize criteria and assess its role in prospective trials, advancing the field toward precision care in VHD.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redefining the role of leadless pacemaker patient selection in light of technological advances and real-world evidence. 根据技术进步和现实证据重新定义无导线起搏器患者选择的作用。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-12 DOI: 10.1080/14779072.2025.2561069

Gianfranco Mitacchione, Emiliano Calvi, Pietro Igor Ponchia, Gianmarco Arabia, Antonio Curnis

引用次数: 0

Are antibiotic-eluting envelopes the solution to cardiac implantable electronic device infections? 抗生素洗脱包膜是心脏植入式电子设备感染的解决方案吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-12 DOI: 10.1080/14779072.2025.2559678

Vassil Traykov

引用次数: 0

Impact of functional status in patients with muscular dystrophy-associated cardiomyopathy on survival after heart transplantation. 肌萎缩相关心肌病患者的功能状态对心脏移植后生存的影响。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-09 DOI: 10.1080/14779072.2025.2559679

Sanath Patil, Nayeem Nasher, T Reese Macmillan, Daler Rahimov, Eugene Storozynsky, J Eduardo Rame, Keshava Rajagopal, John W Entwistle, Charles W Hoopes, Vakhtang Tchantchaleishvili

{"title":"Impact of functional status in patients with muscular dystrophy-associated cardiomyopathy on survival after heart transplantation.","authors":"Sanath Patil, Nayeem Nasher, T Reese Macmillan, Daler Rahimov, Eugene Storozynsky, J Eduardo Rame, Keshava Rajagopal, John W Entwistle, Charles W Hoopes, Vakhtang Tchantchaleishvili","doi":"10.1080/14779072.2025.2559679","DOIUrl":"https://doi.org/10.1080/14779072.2025.2559679","url":null,"abstract":"Background: Heart transplant (HTx) in dystrophy patients has been shown to have a similar survival to cardiomyopathy from other causes, but postoperative rehabilitation remains an issue. This study aimed to review and analyze the reports in the literature to determine whether pre- and post-transplant functional status along with wheelchair dependence in dystrophy patients can influence post-HTx outcomes.Research design and methods: Relevant databases were queried for all case reports and case series regarding HTx in patients with dystrophy-associated cardiomyopathy published in the literature. Clinical data were extracted and tabulated. Patient survival was stratified according to preoperative and postoperative functional status, and Kaplan-Meier survival analysis was performed.Results: We identified 22 studies yielding 36 patients with muscular dystrophy who underwent HTx. At baseline, there were three patients who were wheelchair dependent, and 22 patients had a diminished functional status preoperatively. Overall survival did not differ significantly between patients with normal baseline functional status and those with diminished functional status, either before or after transplantation.Conclusions: Although no significant survival difference was found, diminished functional status, both pre- and post-transplant, appear to be associated with worse survival, highlighting its importance in transplant decision-making.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions. 康瑞洛经皮冠状动脉介入治疗：证据进展、临床应用和未来方向。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-12 DOI: 10.1080/14779072.2025.2544816

Vincenzo De Sio, Felice Gragnano, Arturo Cesaro, Elisabetta Moscarella, Natale Guarnaccia, Antonio Capolongo, Pasquale Maddaluna, Giuseppe Verde, Vincenzo Acerbo, Gianmaria Scherillo, Pierre Sabouret, Daniele Giacoppo, Mattia Galli, Giuseppe Gargiulo, Giovanni Esposito, Marco Valgimigli, Dominick J Angiolillo, Paolo Calabrò

{"title":"Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions.","authors":"Vincenzo De Sio, Felice Gragnano, Arturo Cesaro, Elisabetta Moscarella, Natale Guarnaccia, Antonio Capolongo, Pasquale Maddaluna, Giuseppe Verde, Vincenzo Acerbo, Gianmaria Scherillo, Pierre Sabouret, Daniele Giacoppo, Mattia Galli, Giuseppe Gargiulo, Giovanni Esposito, Marco Valgimigli, Dominick J Angiolillo, Paolo Calabrò","doi":"10.1080/14779072.2025.2544816","DOIUrl":"10.1080/14779072.2025.2544816","url":null,"abstract":"Introduction: Cangrelor is the only parenteral P2Y12 receptor antagonist currently recommended for the prevention of periprocedural thrombotic complications in P2Y12 inhibitor-naïve patients undergoing percutaneous coronary intervention (PCI).Areas covered: This review provides a comprehensive analysis of the pharmacological properties and administration strategies of cangrelor in PCI, summarizes the latest evidence from clinical trials and real-world studies, and discusses potential future directions for its application in clinical practice. Literature search was conducted using PubMed up to May 2025.Expert opinion: Cangrelor provides rapid platelet inhibition following an intravenous bolus, and its short half-life ensures predictable pharmacokinetic profile, facilitating perioperative management. The CHAMPION program demonstrated that cangrelor significantly reduces early ischemic events, including myocardial infarction and stent thrombosis, compared with clopidogrel in patients undergoing PCI. Since its approval, several clinical trials and observational studies have further evaluated the efficacy and safety of cangrelor and its optimal use. The adoption of cangrelor in catheterization laboratories worldwide remains inconsistent, with misuse being frequently reported. Drug-related costs along with concerns surrounding drug interaction when switching to oral P2Y12 inhibitors, limited safety data in high-risk populations and lack of evidence on the comparison against ticagrelor or prasugrel may contribute to its restricted utilization in clinical practice.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"507-519"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supplementation options for low serum T3 in patients with heart failure with reduced ejection fraction: could this revolutionize patient quality of life? 心力衰竭伴射血分数降低患者低血清T3的补充选择：这能彻底改变患者的生活质量吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 DOI: 10.1080/14779072.2025.2554714

Salman Razvi

引用次数: 0

What is the importance of understanding heart disease causes in nonischemic and ischemic cardiomyopathy for left ventricular thrombus patients? 了解左室血栓患者的非缺血性和缺血性心肌病病因的重要性是什么？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-08 DOI: 10.1080/14779072.2025.2544824

Masashi Fujino, Teruo Noguchi

引用次数: 0

High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines. 高apoB/apoA-1比值是主要心脑血管不良事件的一个强有力的风险预测因子。第一部分：更新指南的回顾基础

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-27 DOI: 10.1080/14779072.2025.2543537

Göran Walldius

{"title":"High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines.","authors":"Göran Walldius","doi":"10.1080/14779072.2025.2543537","DOIUrl":"10.1080/14779072.2025.2543537","url":null,"abstract":"Introduction: Hypercholesterolemia and other dyslipidemias are common risk factors for cardiovascular diseases (CVD) and development of atherosclerosis. International guidelines recommend LDL-C, non-HDL-C and apoB under some conditions for clinical use in evaluating risk of CVD. In part 1 of this review newer risk factor data for apoA-1, and the apoB/apoA-1 ratio is presented for cardiovascular, cerebrovascular, diabetes and other CVD manifestations of atherosclerosis. Compared to conventional lipids, these apolipoproteins add strong clinical risk information for these CVD disorders and for a range of other diseases.Areas covered: Prospective studies, reviews, meta-analyses, case control, nested-case and therapeutic studies are analyzed. Searches were conducted with Google and in PubMed, and CVD journals for peer-reviewed publications. In part 2 of this review newer risk factor data for apoA-1, and the apoB/apoA-1 ratio is presented for atherosclerotic plaques, HDL-C versus apoA-1, inflammatory diseases, cancer, and metastases.Expert opinion: Associations between apoB, apoA-1 and especially the apoB/apoA-1 ratio and development of atherosclerosis related risk of multiple CVD diseases have been documented world-wide. This data indicates that the balance, i.e. the ratio between the atherogenic apoB and the protective apoA-1, significantly improves risk evaluation and prediction of CVD, hence calling for an update of guidelines.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"521-545"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term exposure to air pollution and coronary atherosclerosis: understanding the correlation. 长期暴露于空气污染和冠状动脉粥样硬化：了解相关性。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-26 DOI: 10.1080/14779072.2025.2549016

Tomasz Urbanowicz

引用次数: 0

Overcoming an underdiagnosed respiratory condition: should more patients with cardiovascular complications be screened for obstructive sleep apnea? 克服未确诊的呼吸系统疾病：是否应该对更多心血管并发症患者进行阻塞性睡眠呼吸暂停筛查？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-08-27 DOI: 10.1080/14779072.2025.2551668

Andrea Romarheim, Sverre Lehmann, Bjørn Bjorvatn, Sahrai Saeed

{"title":"Overcoming an underdiagnosed respiratory condition: should more patients with cardiovascular complications be screened for obstructive sleep apnea?","authors":"Andrea Romarheim, Sverre Lehmann, Bjørn Bjorvatn, Sahrai Saeed","doi":"10.1080/14779072.2025.2551668","DOIUrl":"https://doi.org/10.1080/14779072.2025.2551668","url":null,"abstract":"Introduction: Obstructive sleep apnea (OSA) - characterized by recurrent upper airway obstruction during sleep - remains underdiagnosed and undertreated. Affecting nearly one billion adults globally, OSA is especially prevalent among patients with cardiovascular comorbidities. Diagnosis may be delayed due to atypical symptoms, particularly in women, and healthcare barriers including fragmented care, limited provider training, and restricted access to specialized diagnostics. Untreated OSA contributes to an increased prevalence of resistant hypertension, recurrent arrhythmias (atrial fibrillation), stroke, and heart failure.Areas covered: This review focuses on the intricate relationship between OSA and cardiovascular health, highlighting key pathophysiological mechanisms such as intermittent hypoxia, autonomic dysregulation, and systemic inflammation that drive structural and functional cardiac impairments. Further, the review highlights the importance of improved screening tools for early detection. The special report is based on systemic search of PubMed.Expert opinion: Early screening and detection are crucial, given the strong association between untreated OSA and adverse health outcomes. Expert consensus recommends routine OSA screening in high-risk cardiovascular populations and emphasizes comprehensive early interventions; CPAP, lifestyle modification, and metabolic risk management. Integrating OSA assessment into cardiology practice and expanding advanced diagnostic tools may improve detection, reduce morbidity and mortality, and lessen the economic burden on healthcare systems.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0